Vaccine Shows Promise Against Advanced Cancers

Monday, 04 Mar 2013 11:25 AM

By Nick Tate

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
An experimental cancer vaccine developed by Virginia Commonwealth University scientists has been found to be surprisingly effective at targeting advanced cases and tumors that have spread to other parts of the body.
 
Although the breakthrough, reported in the journal Cancer Research, is preliminary and requires additional study, the findings are so promising the researchers suggest the novel immunotherapy could become a potent new weapon against so-called metastatic cancers when used in combination with current cancer therapies.
 
"Successfully promoting antitumor immunity will help eradicate tumor cells, control cancer progression and help prevent tumor relapse," said lead researcher author Xiang-Yang Wang, an associate professor of Human and Molecular Genetics at VCU School of Medicine. "This immunotherapy has the potential to be used alone or in combination with conventional cancer treatments to develop and establish immune protection against cancer and its metastases."
 
Special: These 5 Things Flush 40 lbs. of Fat Out of Your Body.

The vaccine contains a molecule engineered by Wang — called Flagrp-170 — that he tested on animal and human melanoma, prostate, and colon tumor cells. Wang and his colleagues designed the vaccine to be delivered by modified viruses directly to the tumor sites — like molecular Trojan Horses — to target the cancer. The results showed that the vaccine provoked a profound immune response that significantly prolonged survival in the treated animals.
 
Grp170 has been shown to help the immune system recognize cancer antigens — molecules from foreign objects such as bacteria, viruses or cancer that, when detected, provoke an immune response aimed at attacking them. Cancer cells have unique mechanisms that allow them to suppress immune responses, but the vaccine may circumvent that process.
 
"Overcoming cancer's ability to suppress the body's natural immune responses and restore or develop immunity for tumor eradication is the goal of cancer immunotherapy," said Wang. "More experiments are needed, but we are hoping Flagrp-170 may one day be used in formulating more effective therapeutic cancer vaccines."
 
The study was funded, in part, by the National Institutes of Health.

© 2014 NewsmaxHealth. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Weight Loss Surgery Brings Risk of Severe Headaches: Study

Wednesday, 22 Oct 2014 17:21 PM

After weight-loss surgery, some patients may be at risk for developing severe headaches, a new study suggests.
In  . . .

Y Chromosome Loss Predicts Shortened Lifespan in Men

Wednesday, 22 Oct 2014 17:16 PM

Elderly men who've lost the Y chromosome from their blood cells maybe at increased risk for earlier death and death from . . .

IVF Babies Have Slightly Higher Risk of Birth Defects: Study

Wednesday, 22 Oct 2014 17:04 PM

The risk of birth defects is low among children conceived using assisted reproductive technologies (ART), according to a . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved